0001477932-18-005520.txt : 20181114 0001477932-18-005520.hdr.sgml : 20181114 20181114144421 ACCESSION NUMBER: 0001477932-18-005520 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Applied BioSciences Corp. CENTRAL INDEX KEY: 0001607549 STANDARD INDUSTRIAL CLASSIFICATION: HEATING EQUIP, EXCEPT ELEC & WARM AIR & PLUMBING FIXTURES [3430] IRS NUMBER: 811699502 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55523 FILM NUMBER: 181182847 BUSINESS ADDRESS: STREET 1: 9701 WILSHIRE BLVD. STREET 2: SUITE 1000 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: (310) 356-7374 MAIL ADDRESS: STREET 1: 9701 WILSHIRE BLVD. STREET 2: SUITE 1000 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: Stony Hill Corp. DATE OF NAME CHANGE: 20161109 FORMER COMPANY: FORMER CONFORMED NAME: First Fixtures, Inc. DATE OF NAME CHANGE: 20140507 10-Q 1 appb_10q.htm FORM 10-Q appb_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File No. 000-55523

 

APPLIED BIOSCIENCES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

None

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

9701 Wilshire Blvd., Suite 1000

Beverly Hills, California 90212

(Address of principal executive offices) (Zip Code)

 

(310) 356-7374

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

 

Large accelerated filer

o

Accelerated filer

o

Non-accelerated filer

o

Smaller reporting company

x

(Do not check if a smaller reporting company)

Emerging growth company

o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes ¨ No x

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

As of November 9, 2018 there were 11,772,113 shares of common stock, $0.00001 par value per share, outstanding.

 

 
 
 
 

 

APPLIED BIOSCIENCES CORP.

QUARTERLY REPORT ON FORM 10-Q

FOR THE PERIOD ENDED SEPTEMBER 30, 2018

 

INDEX

 

Index

 

Page

 

 

 

Part I. Financial Information

 

 

 

Item 1.

Unaudited Condensed Consolidated Financial Statements

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2018 (Unaudited) and March 31, 2018.

 

4

 

 

 

Condensed Unaudited Consolidated Statements of Operations for the three and six months ended September 30, 2018 and September 30, 2017.

 

5

 

 

 

Condensed Unaudited Consolidated Statements of Stockholders’ Equity for the six months ended September 30, 2018.

 

6

 

 

 

Condensed Unaudited Consolidated Statement of Cash Flows for the six months ended September 30, 2018 and September 30, 2017.

 

7

 

 

 

Notes to Condensed Consolidated Financial Statements (Unaudited).

 

8

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

14

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

 

18

 

 

Item 4.

Controls and Procedures.

 

18

 

 

 

Part II. Other Information

 

 

 

Item 1.

Legal Proceedings.

 

19

 

 

Item 1A.

Risk Factors.

 

19

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

 

19

 

 

Item 3.

Defaults Upon Senior Securities.

 

19

 

 

Item 4.

Mine Safety Disclosures.

 

19

 

 

Item 5.

Other Information.

 

19

 

 

Item 6.

Exhibits.

 

20

 

 

 

Signatures

 

21

 

 

 
2
 
Table of Contents

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q of Applied Biosciences Corp., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the possibility that we will not receive sufficient customers to grow our business, the Company’s need for and ability to obtain additional financing, other factors over which we have little or no control; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).

 

Our management has included projections and estimates in this Form 10-Q, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

 
3
 
Table of Contents

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial statements.

 

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS 

 

 

 

September 30, 2018

 

 

March 31, 2018

 

ASSETS

 

(unaudited)

 

 

 

Current Assets

 

 

 

 

 

 

Cash

 

$ 6,924

 

 

$ 60,934

 

Accounts receivable, net of allowance of nil and $2,227 at September 30, 2018 (unaudited) and March 31, 2018, respectively

 

 

11,065

 

 

 

12,386

 

Inventory

 

 

51,672

 

 

 

29,074

 

Prepaids and other current assets

 

 

54,455

 

 

 

124,455

 

Total Current Assets

 

 

124,116

 

 

 

226,849

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

3,855

 

 

 

4,441

 

Equity investments

 

 

873,300

 

 

 

468,537

 

Other asset

 

 

5,500

 

 

 

5,500

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$ 1,006,771

 

 

$ 705,327

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$ 39,749

 

 

$ 21,846

 

Convertible note payable, net of debt discount of $85,890 at September 30, 2018

 

 

78,610

 

 

 

-

 

Accrued expenses

 

 

238,029

 

 

 

14,039

 

Total Current Liabilities

 

 

356,388

 

 

 

35,885

 

Stockholders’ Equity

 

 

 

 

 

 

 

 

Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none

 

 

 

 

 

 

 

 

issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018

 

 

-

 

 

 

-

 

Common stock; $0.00001 par value; 200,000,000 shares

 

 

 

 

 

 

 

 

authorized; 10,677,110 and 10,499,610 issued and outstanding at

 

 

 

 

 

 

 

 

September 30, 2018 (unaudited) and March 31, 2018, respectively

 

 

107

 

 

 

105

 

Additional paid in capital

 

 

3,538,900

 

 

 

3,054,297

 

Common stock to be issued, 212,000 and 263,000 shares at

 

 

 

 

 

 

 

 

September 30, 2018 (unaudited) and March 31, 2018, respectively

 

 

537,852

 

 

 

526,000

 

Accumulated deficit

 

 

(3,407,857 )

 

 

(2,901,933 )

Total Applied BioSciences Corp. Stockholders’ Equity

 

 

669,002

 

 

 

678,469

 

Non-controlling interest

 

 

(18,619 )

 

 

(9,027 )

Total Stockholders’ Equity

 

 

650,383

 

 

 

669,442

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$ 1,006,771

 

 

$ 705,327

 

 

 The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
4
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

Three Months

 

 

Three Months

 

 

Six Months

 

 

Six Months

 

 

 

Ended

 

 

Ended

 

 

Ended

 

 

Ended

 

 

 

September 30, 2018

 

 

September 30, 2017

 

 

September 30, 2018

 

 

September 30, 2017

 

 

 

(unaudited)

 

 

(unaudited)

 

 

(unaudited)

 

 

(unaudited)

 

PRODUCT REVENUE, NET

 

$ 48,966

 

 

$ 61,279

 

 

$ 59,400

 

 

$ 116,611

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE, PRODUCT

 

 

42,400

 

 

 

52,443

 

 

 

60,158

 

 

 

90,389

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS MARGIN (LOSS)

 

 

6,566

 

 

 

8,836

 

 

 

(758 )

 

 

26,222

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

111,393

 

 

 

45,496

 

 

 

455,437

 

 

 

65,061

 

General and administrative

 

 

188,052

 

 

 

84,619

 

 

 

395,198

 

 

 

223,516

 

Depreciation and Amortization

 

 

292

 

 

 

56,128

 

 

 

585

 

 

 

112,256

 

TOTAL OPERATING EXPENSES

 

 

299,737

 

 

 

186,243

 

 

 

851,220

 

 

 

400,833

 

OPERATING LOSS

 

 

(293,171 )

 

 

(177,407 )

 

 

(851,978 )

 

 

(374,611 )

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

245,834

 

 

 

-

 

 

 

404,763

 

 

 

-

 

Interest Expense

 

 

(66,422 )

 

 

-

 

 

 

(68,301 )

 

 

-

 

Total other income, net

 

 

179,412

 

 

 

-

 

 

 

336,462

 

 

 

-

 

NET LOSS

 

 

(113,759 )

 

 

(177,407 )

 

 

(515,516 )

 

 

(374,611 )

Less: Net loss (income) attributable to non controlling interest

 

 

3,336

 

 

 

57

 

 

 

9,592

 

 

 

(1,139 )

NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.

 

$ (110,423 )

 

$ (177,350 )

 

$ (505,924 )

 

$ (375,750 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS PER COMMON SHARE

 

$ (0.01 )

 

$ (0.01 )

 

$ (0.05 )

 

$ (0.02 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE SHARES OUTSTANDING

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

10,677,110

 

 

 

15,320,154

 

 

 

10,617,332

 

 

 

15,268,914

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
5
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2018 (UNAUDITED)

 

 

 

Common Stock $0.00001 Par

 

 

Common

Stock

to be

 

 

Additional

Paid In

 

 

Non-
Controlling

 

 

Accumulated

 

 

Stockholders’

 

 

 

Number

 

 

Amount

 

 

Issued

 

 

Capital

 

 

Interest

 

 

Deficit

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2018

 

 

10,499,610

 

 

$ 105

 

 

$ 526,000

 

 

$ 3,054,297

 

 

$ (9,027 )

 

$ (2,901,933 )

 

$ 669,442

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock previously committed but not issued

 

 

50,000

 

 

 

1

 

 

 

(100,000 )

 

 

99,999

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for cash

 

 

12,500

 

 

 

 

 

 

 

50,000

 

 

 

25,000

 

 

 

 

 

 

 

 

 

 

 

75,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of shares issued to consultant for services

 

 

90,000

 

 

 

1

 

 

 

61,852

 

 

 

179,999

 

 

 

 

 

 

 

 

 

 

 

241,852

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of shares issued to advisory board member

 

 

25,000

 

 

 

-

 

 

 

 

 

 

 

51,000

 

 

 

 

 

 

 

 

 

 

 

51,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Beneficial conversion feature associated with a convertible note

 

 

 

 

 

 

 

 

 

 

 

 

 

 

128,605

 

 

 

 

 

 

 

 

 

 

 

128,605

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,592 )

 

 

(505,924 )

 

 

(515,516 )

Balance, September 30, 2018 (unaudited)

 

 

10,677,110

 

 

$ 107

 

 

$ 537,852

 

 

$ 3,538,900

 

 

$ (18,619 )

 

$ (3,407,857 )

 

$ 650,383

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
6
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

Six Months

 

 

Six Months

 

 

 

Ended

 

 

Ended

 

 

 

September 30, 2018

 

 

September 30, 2017

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

(unaudited)

 

 

(unaudited)

 

Net loss

 

$ (515,516 )

 

$ (374,611 )

Adjustment to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

(404,763 )

 

 

 

 

Amortization of debt discount

 

 

42,715

 

 

 

-

 

Fair value of shares issued to consultants

 

 

255,352

 

 

 

50,000

 

Depreciation

 

 

586

 

 

 

-

 

Amortization of intangible

 

 

-

 

 

 

112,256

 

Changes in operating assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable

 

 

1,321

 

 

 

(3,392 )

Inventory

 

 

(22,598 )

 

 

(7,648 )

Prepaid and other current assets

 

 

107,500

 

 

 

1,382

 

Accounts payable and accrued expenses

 

 

241,893

 

 

 

11,805

 

Net cash used in operating activities

 

 

(293,510 )

 

 

(210,208 )

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Acquisition of equity investment

 

 

-

 

 

 

(50,000 )

Net cash used in investing activities

 

 

-

 

 

 

(50,000 )

 

 

 

 

 

 

 

 

 

CASH FLOW FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Issuance of convertible note

 

 

164,500

 

 

 

-

 

Issuance of common stock for cash

 

 

75,000

 

 

 

195,055

 

Net cash provided by financing activities

 

 

239,500

 

 

 

195,055

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

 

(54,010 )

 

 

(65,153 )

 

 

 

 

 

 

 

 

 

CASH, BEGINNING OF PERIOD

 

 

60,934

 

 

 

212,637

 

 

 

 

 

 

 

 

 

 

CASH, END OF PERIOD

 

$ 6,924

 

 

$ 147,484

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Fair value of shares issued to consultants recorded as prepaid

 

$ 37,500

 

 

$ -

 

Fair value of beneficial conversion feature related to issuance of convertible notes

 

$ 128,605

 

 

$ -

 

Increase in cash held in trust account from sale of common stock

 

$ -

 

 

$ 499,945

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
7
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

 

Description of the Company

 

Applied BioSciences Corp. (formerly First Fixtures, Inc. and Stony Hill Corp. or the “Company”) was incorporated in the State of Nevada on February 21, 2014 and established a fiscal year end of March 31. Effective October 24, 2016 the Company changed its name from First Fixtures Inc. to Stony Hill Corp and on March 6, 2018, the Company changed its name from Stony Hill Corp. to Applied BioSciences Corp. The Company is focused on multiple areas of the hemp and CBD industry. Specifically, the Company is focused on select investments, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

 

Basis of presentation – Unaudited Financial Statements

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019, or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended March 31, 2018, which are included in the Company’s Report on Form 10-K for such year filed on June 28, 2018.

 

Going concern

 

These condensed statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As reflected in the condensed consolidated financial statements, the Company incurred a net loss of $515,516 and used $293,510 of cash in operating activities during the six months ended September 30, 2018. Further, the Company’s independent auditor in their audit report for fiscal year ended March 31, 2018 expressed substantial doubt about the Company’s ability to continue as a going concern. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and income from operations. During the six months ended September 30, 2018, the Company sold 37,500 shares of its common stock to accredited investors at a price of $2.00 per share for total proceeds of $75,000 and issued three separate convertible notes for a total amount of $164,500 both in private placements to accredited investors. However, the Company will need and is currently working on obtaining additional funds to operate its business through and beyond the date of this Form 10-Q filing. There is no assurance that such funds will be available or at terms acceptable to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions and covenants on its operations, in the case of debt financing or cause substantial dilution for its stockholders in the case of convertible debt and equity financing.

 

 
8
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.

 

Reclassification of Certain Prior Year Information 

 

The Company has reclassified prior year sales and marketing expenses of $45,496 and $65,061 for the three and six months ended September 30, 2017, respectively, that were previously included in general and administrative expenses in the condensed consolidated statements of operations to conform to the current year presentation. The reclassification of sales and marketing expenses had no impact on net loss or cash flows.

 

Use of Estimates and Assumptions

 

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

 

Revenue Recognition

 

The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. 

 

Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.

 

The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

 

Advertising

 

The Company expenses advertising costs as incurred. Advertising expense for the three and six months ended September 30, 2018 amounted to $111,392 and $455,437, respectively, and $45,496 and $65,061 for the three and six months ended September 30, 2017 and are included in “Sales and Marketing expenses” in the Condensed Consolidated Statements of Operations.

 

 
9
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

Earnings (Loss) per Share

 

The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.

 

Investments

 

Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.

 

On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.

 

Investments accounted for as above are included in the caption “Equity investments” on the Condensed Consolidated Balance Sheets.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

NOTE 3 – INVESTMENTS

 

Equity investments relate to purchases of stock in certain entities with ownership percentages of less than 5%. As of March 31, 2018, these investments were recorded at their cost basis. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, and as such, these investments were recorded at their market value as of September 30, 2018. The investments consist of the following:

 

 
10
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

 

 

September 30, 2018

 

 

March 31, 2018

 

(A)    Cannabi-Tech Ltd.

 

$ 68,537

 

 

$ 68,237

 

(B)    Hightimes Holdings Corp.

 

 

654,763

 

 

 

250,000

 

(C)    Precision Cultivation Systems, LLC

 

 

50,000

 

 

 

50,000

 

(D)    Bailey Venture Partners XII LLC (JUUL)

 

 

100,000

 

 

 

100,000

 

 

 

$ 873,300

 

 

$ 468,537

 

 

(A) In November 2016, the Company purchased 29,571 shares of Preferred A stock of Cannabi-Tech Ltd. (“Cannabi”), at a price of $1.69086 per share for total investment of $50,000. In October 2017, the Company purchased 7,309 shares of Preferred A-1 stock of Cannabi at a price of $2.536 per share for total investment of $18,537. As of March 31, 2018, total investment amounted to $68,537, which accounts for less than 5% in Cannabi. Cannabi is a private company incorporated in the State of Israel that provides lab-grade medical cannabis quality control testing systems used to test the quality of medical marijuana flowers. The fair value of the investment at September 30, 2018 approximated its cost basis.

 

(B) In January 2017, the Company entered in to an agreement to purchase 59,524 shares of Class A common stock at a price of $4.20 per share for total investment of $250,000, which accounts for less than 5% investment in Hightimes Holdings Corp. (“Hightimes”). Hightimes owns Hight Times Magazine and hosts festivals, events and competitions including the High Times Cannabis Cup and multiple e-commerce properties, including HighTimes.com, CannabisCup.com and 420.com. As of September 30, 2018, the Company was able to obtain observable evidence that the investment had a market value of $11.00 per share, or an aggregate value of $654,763. As such, the Company recorded an unrealized gain from the change in market value of $404,763 during the six months ended September 30, 2018.

 

(C) In June 2017, the Company entered in a Subscription Agreement to purchase 0.5% interest in Precision Cultivation Systems, LLC (“Precision”), a Delaware limited liability company, for a purchase price of $50,000. Precision is developing a growth system that capitalizes on a patent-pending cultivation method that utilizes proprietary irrigation and root zone conditioning. As part of the Subscription Agreement, $42,500 of the investment is subject to repayment on a pro-rata basis with other investors who have entered into similar Subscription Agreements. Amounts subject to repayment are solely at the discretion of Precision. The fair value of the investment at September 30, 2018 approximated its cost basis.

 

(D) In January 2018, the Company paid $100,000 for the purchase of a Membership Interest in Bailey Venture Partners XII LLC (“Bailey”) representing less than 5% interest in Bailey. Along with other funds received from third-party investors, Bailey plans to invest funds received in various strategic investments. The Company recorded this investment at cost and will recognize dividends, if any, when received, and will recognize gains or loss upon either selling the securities or recognize a loss prior to selling the securities if there is evidence that the fair market value of the investment has declined to below the recorded historical cost. The fair value of the investment at September 30, 2018 approximated its cost basis.

 

As the Company does not participate in the management of these companies nor has the ability to exercise significant influence over these companies, the Company recorded these investments at cost, and as of April 1, 2018, will adjust the cost basis to market at the end of each reporting period. Dividends, if any, will be recognized when received.

 

NOTE 4 – CONVERTIBLE NOTE

 

During the six months ended September 30, 2018, the Company issued three separate Convertible Promissory Notes (“Notes”) having a total available principal amount of $250,000 to the same holder of which the Company borrowed $164,500 as of September 30, 2018. All outstanding principal together with interest on this Note is due and payable on December 31, 2018 and accrue interest at 8% per month. The note holder, at its sole discretion and election, may convert any part or all of the then outstanding principal and/or interest on these Notes into shares of common stock of the Company at a fixed price per share of $1.00. As the conversion price of $1.00 reflected a price discount below the fair market value of the Company’s common stock as of the date of the receipt of proceeds, there was deemed a beneficial conversion feature associated with these Notes. As such, the Company recorded $128,605 in additional paid-in capital and debt discount representing the intrinsic value of the beneficial conversion feature at the date of the borrowing against the Notes. The value of the beneficial conversion feature is being amortized over the term of the Notes of which $42,715 was amortized and reflected as interest expense for the six months ended September 30, 2018. As of September 30, 2018, the unamortized debt discount was $85,890. As of September 30, 2018, the balance of the $164,500 note, net of the unamortized discount of $85,890 was $78,610.

 

 
11
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

In view of the Company’s limited operations and resources, none of the Company’s directors and/or officers received any compensation from the Company during the six months ended September 30, 2018.

 

NOTE 6 – EQUITY

 

Common Stock to be Issued

 

On February 23, 2017, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with mCig, Inc., a Nevada corporation (“mCig”) consisting of the issuance of an aggregate of 350,000 shares of common stock. Of the 350,000 shares of common stock consideration, 150,000 shares or $426,000 have not been issued as of March 31, 2018 and have been included in “Common stock to be issued” in the accompanying condensed consolidated statement of stockholders’ equity. During the six months ended September 30, 2018, the Company issued 50,000 shares of common stock valued at $100,000 which was previously reflected as “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity.

 

During the six months ended September 30, 2018, the Company sold 37,500 shares of common stock, of which 25,000 shares had not been issued as of September 30, 2018 and is reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity. The shares were sold at a price of $2.00 per share for total proceeds of $75,000 pursuant to a private placement Subscription Agreement with accredited investors. The Subscription Agreement offered up to one million shares of the Company’s common stock at a price per share of $2.00 per share. The Company made this offering solely to accredited investors, as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

 

Establishment of Advisory Board and Adoption of Charter

 

On April 28, 2017, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. The Advisory Board shall be comprised of one or more directors (“Advisors”), and up to nine independent, non-Board, non-employee members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.

 

During the six months ended September 30, 2018, the Company appointed another Advisor to the Advisory Board, which entitled him to an annual consulting fee 25,000 shares of the Company’s stock for a term of 6 months, with total fair value of $51,000.

 

Shares Issued for Services

 

During the six months ended September 30, 2018, the Company granted an aggregate of 99,500 shares of its common stock to three (3) consultants as payment for services rendered to the Company and recorded expense of $241,852 based on the fair value of the Company’s common stock at grant dates. Of the 99,500 shares granted, 62,000 shares valued at $61,852 had not been issued as of September 30, 2018, and were reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity during the period then ended.

 

 
12
 
Table of Contents

 

APPLIED BIOSCIENCES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017

(unaudited)

 

NOTE 7 – SUBSEQUENT EVENTS

 

Common Stock Purchase Agreement

 

On October 15, 2018, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Triton Funds, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which the Purchaser has the right to right to purchase up to $1,000,000 of shares of common stock (the “Shares”) of the Company at a purchase price equal to 75% of the lowest closing price of the common stock of the Company on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than $300,000 of common stock of the Company within a period of every 30 business days. The Company has the right to terminate the Purchase Agreement at any time, and the Purchase Agreement shall terminate automatically on June 30, 2019, unless earlier terminated. The Purchase Agreement also contains customary representations, warranties, and covenants by, among, and for the benefit of the parties.

 

On October 15, 2018, the Company entered into a non-binding letter agreement, pursuant to which the Company intends to issue 25,000 shares of common stock to the Purchaser, pursuant to a Share Donation Agreement to be entered into by and between the Company and the Purchaser at a future, unspecified date. The Company anticipates making the issuance of 25,000 shares on a date before December 31, 2018.

 

The Company’s offering of the Shares to the Purchaser is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Act (in that the Shares were offered by us in a transaction not involving any public offering) and pursuant to Rule 506 of Regulation D, promulgated thereunder.

 

 
13
 
Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This section of this Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

 

Results of Operations

 

Our revenue, operating expenses, and net loss from operations for our three and six months ended September 30, 2018 as compared to our three and six months ended September 30, 2017 were as follows:

 

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

 

 

 

Three Months

 

 

Three Months

 

 

 

 

 

 

 

Ended

 

 

Ended

 

 

 

 

Percentage

 

 

 

September 30,

2018

 

 

September 30,

2017

 

 

$ Change

Inc (Dec)

 

 

Change

Inc (Dec)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PRODUCT REVENUE, NET

 

$ 48,966

 

 

$ 61,279

 

 

$ (12,313 )

 

 

(20 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE, PRODUCT

 

 

42,400

 

 

 

52,443

 

 

 

(10,043 )

 

 

(19 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS) MARGIN

 

 

6,566

 

 

 

8,836

 

 

 

(2,270 )

 

 

(26 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

111,393

 

 

 

45,496

 

 

 

65,897

 

 

 

145 %

General and administrative

 

 

188,052

 

 

 

84,619

 

 

 

103,433

 

 

 

122 %

Depreciation and Amortization

 

 

292

 

 

 

56,128

 

 

 

(55,836 )

 

 

(99 )%

TOTAL OPERATING EXPENSES

 

 

299,737

 

 

 

186,243

 

 

 

113,494

 

 

 

61 %

OPERATING LOSS

 

 

(293,171 )

 

 

(177,407 )

 

 

115,764

 

 

 

65 %

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

245,834

 

 

 

-

 

 

 

245,834

 

 

 

-

 

Interest Expense

 

 

(66,422 )

 

 

-

 

 

 

(66,422 )

 

 

-

 

Total other income, net

 

 

179,412

 

 

 

-

 

 

 

179,412

 

 

 

-

 

NET LOSS

 

 

(113,759 )

 

 

(177,407 )

 

 

(63,648 )

 

 

(36 )%

Less: Net loss attributable to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

non controlling interest

 

 

3,336

 

 

 

57

 

 

 

3,279

 

 

 

5753 %

NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.

 

$ (110,423 )

 

$ (177,350 )

 

$ (66,927 )

 

 

(38 )%

 

Revenues: Revenue from products relate to shipments of cannabidiol (“CBD”) brand products. During the three months ended September 30, 2018, we earned revenue from our CBD product lines of $48,966 as compared to $61,279 for the three months ended September 30, 2017. The decrease of $12,313 relates to our efforts to replace then existing CBD products and change our product lines and branding to our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products. This required our change in marketing, branding, labeling and warehousing which ultimately caused sales to temporarily slow until we relaunched our new CBD products during our current fiscal year.

 

Cost of Goods Sold: Cost of goods sold consists of purchases of CBD product inventory for sale. During the three months ended September 30, 2018, we incurred $42,400 of costs primarily related to product purchases and labeling of new products as compared to $52,443 for the three months ended September 30, 2017. The decrease of $10,043 reflects our refocus and launch of new products during our current fiscal year.

 

Gross Margin: Gross margin comprised from our sale of products and was $6,566 for the three months ended September 30, 2018 as compared to $8,836 for the three months ended September 30, 2017. The decrease of $2,270 reflects our refocus and launch of new CBD products during our current fiscal year.

 

Sales and Marketing: Sales and marketing expenses mainly comprised of advertising, public relations, events, and website marketing costs. Sales and marketing expenses increased $65,897 to $111,393 for the three months ended September 30, 2018 as compared to $45,496 for the three months ended September 30, 2017. The majority of the increase related to public relation services, website marketing development and increased advertising and promotion costs.

 

 
14
 
Table of Contents

 

General and Administrative: General and administrative expenses mainly comprised of professional fees, travel expenses, meals and entertainment and other office support costs. General and administrative expenses increased $103,433 to $188,052 for the three months ended September 30, 2018 as compared to $84,619 for the three months ended September 30, 2017. The majority of the increase related to higher professional and advisory fees and other supportive general and administrative expenses.

 

Depreciation and Amortization: Depreciation expense was $292 for the three months ended September 30, 2018 as compared to $56,128 for the three months ended September 30, 2017. The decrease relates to amortization during our three months ended September 30, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the three months ended September 30, 2018.

 

Unrealized Gain on Equity Investments: During the three months ended September 30, 2018, we were able to obtain observable evidence that an investment we own had increased by $4.13 per share for an aggregate value of $654,763, which was $245,834 higher than the fair value of this investment in the previous quarter. As such, we recorded an unrealized gain from the change in market value of $245,834 during the three months ended September 30, 2018.

 

Interest Expense: During the three months ended September 30, 2018, we recorded $66,422 of interest costs related to convertible notes that we entered into during our current fiscal year.

 

Six Months Ended September 30, 2018 Compared to Six Months Ended September 30, 2017

 

 

 

Six Months

 

 

Six Months

 

 

 

 

 

 

 

Ended

 

 

Ended

 

 

 

 

Percentage

 

 

 

September 30,

2018

 

 

September 30,

2017

 

 

$ Change

Inc (Dec)

 

 

Change

Inc (Dec)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PRODUCT REVENUE, NET

 

$ 59,400

 

 

$ 116,611

 

 

$ (57,211 )

 

 

(49 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE, PRODUCT

 

 

60,158

 

 

 

90,389

 

 

 

(30,231 )

 

 

(33 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS) MARGIN

 

 

(758 )

 

 

26,222

 

 

 

(26,980 )

 

 

(103 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

455,437

 

 

 

65,061

 

 

 

390,376

 

 

 

600 %

General and administrative

 

 

395,198

 

 

 

223,516

 

 

 

171,682

 

 

 

77 %

Depreciation and Amortization

 

 

585

 

 

 

112,256

 

 

 

(111,671 )

 

 

(99 )%

TOTAL OPERATING EXPENSES

 

 

851,220

 

 

 

400,833

 

 

 

450,387

 

 

 

112 %

OPERATING LOSS

 

 

(851,978 )

 

 

(374,611 )

 

 

477,367

 

 

 

127 %

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

404,763

 

 

 

-

 

 

 

404,763

 

 

 

-

 

Interest Expense

 

 

(68,301 )

 

 

-

 

 

 

(68,301 )

 

 

-

 

Total other income, net

 

 

336,462

 

 

 

-

 

 

 

336,462

 

 

 

-

 

NET LOSS

 

 

(515,516 )

 

 

(374,611 )

 

 

140,905

 

 

 

38 %

Less: Net loss attributable to non controlling interest

 

 

9,592

 

 

 

(1,139 )

 

 

10,731

 

 

 

942 %

NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.

 

$ (505,924 )

 

$ (375,750 )

 

$ 130,174

 

 

 

35 %

 

Revenues: During the six months ended September 30, 2018, we earned revenue from our CBD product lines of $59,400 as compared to $116,611 for the six months ended September 30, 2017. The decrease of $57,211 relates to our efforts to replace then existing CBD products and change our product lines and branding to our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products. This required our change in marketing, branding, labeling and warehousing which ultimately caused sales to temporarily slow until we relaunched our new CBD products during our current fiscal year.

 

 
15
 
Table of Contents

 

Cost of Goods Sold: During the six months ended September 30, 2018, we incurred $60,158 of costs primarily related to product purchases and labeling of new products as compared to $90,389 for the six months ended September 30, 2017. The decrease of $30,231 reflects our refocus and launch of new products during our current fiscal year.

 

Gross (Loss) Margin: Gross (loss) margin comprised from our sale of products and was a gross loss of $758 for the six months ended September 30, 2018 as compared to a gross margin of $26,222 for the six months ended September 30, 2017. The decrease of $26,980 reflects our refocus and launch of new CBD products during our current fiscal year.

 

Sales and Marketing: Sales and marketing expenses increased $390,376 to $455,437 for the six months ended September 30, 2018 as compared to $65,061 for the six months ended September 30, 2017. The majority of the increase related to public relation services, website marketing development and increased advertising and promotion costs.

 

General and Administrative: General and administrative expenses increased $171,682 to $395,198 for the six months ended September 30, 2018 as compared to $223,516 for the six months ended September 30, 2017. The majority of the increase related to higher professional fees and general and administrative expenses.

 

Depreciation and Amortization: Depreciation expense was $585 for the six months ended September 30, 2018 as compared to $112,256 for the six months ended September 30, 2017. The decrease relates to amortization during our six months ended September 30, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the six months ended September 30, 2018.

 

Unrealized Gain on Equity Investments: During the six months ended September 30, 2018, we were able to obtain observable evidence that an investment we own had increased by $6.80 per share for an aggregate value of $654,763, which was $404,763 higher than our original purchase price for this investment. As such, we recorded an unrealized gain from the change in market value of $404,763 during the six months ended September 30, 2018.

 

Interest Expense: During the six months ended September 30, 2018, we recorded $68,301 of interest costs related to a convertible notes that we entered into during the six months ended September 2018.

 

Liquidity and Capital Resources

 

Cash Flows

 

A summary of our cash flows for the six months ended September 30, 2018 is as follows:

 

Net cash used in operating activities was $293,510 for the six months ended September 30, 2018 as compared to $210,208 for the six months ended September 30, 2017. The increase in use of cash in operations mainly related to higher general and administrative and sales and marketing expenses from our operations.

 

Net cash used in investing activities was nil during the six months ended September 30, 2018 as compared to $50,000 during the six months ended September 30, 2017, which comprised of a $50,000 equity investment we made during that period.

 

Net cash provided by financing activities for the six months ended September 30, 2018 was $239,500 as compared to $195,055 for the six months ended September 30, 2017. The amounts received during our six months ended September 30, 2018 related to $75,000 from proceeds from the sale of shares of our common stock and $164,500 received from three convertible notes. The amounts received during our six months ended September 30, 2017 related to our issuance of our common stock for cash.

 

 
16
 
Table of Contents

 

Going Concern

 

As reflected in the condensed consolidated financial statements contained elsewhere is this Form 10-Q, as of September 30, 2018 we had cash on hand and had an accumulated deficit of $6,924 and $3,407,857, respectively, and during the six months ended September 30, 2018, we utilized cash for operations and incurred a net loss of $293,510 and $515,516, respectively. Our uses of cash have been primarily for strategic investments we made and operations and marketing efforts to promote and develop our CBD products and our company. Our principal sources of liquidity have been cash provided by financing, primarily through the sale of equity securities and issuance of convertible notes, along with revenues from our principal business activities. Further, we have used cash for various strategic investments for which we typically receive returns when such investments are sold and when or if dividends are declared.

 

As of the date of this Form 10-Q, our cash resources are insufficient to meet our current operating expense requirements and planned business objectives without additional financing. Our ability to continue as a going concern is dependent on our ability to raise additional capital and to ultimately achieve sustainable revenues and income from our operations. During the six months ended September 30, 2018, we raised $75,000 through the receipt of Subscription Agreements (“Subscription”) where we sold 37,500 shares of our common stock to accredited investors at a price of $2.00 per share. We also received during the six months ended September 30, 2018 $164,500 from the issuance of convertible notes to an investor. However, we anticipate that significant additional expenditures will be necessary to expand and bring to market our products and investments before sufficient and consistent positive operating cash flows will be achieved. As such, we will need additional funds to operate our business through and beyond the date of this Form 10-Q filing.

 

To address our capital requirements, in October 2018 we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Triton Funds, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which the Purchaser has the right to purchase up to $1,000,000 of our shares of common stock (the “Shares”) at a purchase price equal to 75% of the lowest closing price of our common stock on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than $300,000 worth of our shares of common stock within a consecutive period of 30 business days. However, we anticipate that additional funds will be needed to continue operations, obtain profitability and to achieve our objectives. There can be no assurance that such funds will be available or at terms acceptable to us. Even if we are able to obtain additional financing, it may contain undue restrictions and covenants on our operations, in the case of debt financing or cause substantial dilution for our stockholders in the case of convertible debt and equity financing.

 

These and other factors raise substantial doubt about our ability to continue as a going concern. Further, our independent auditors in their audit report for our fiscal year ended March 31, 2018 expressed substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

 

Summary of Significant Accounting Policies

 

Use of Estimates

 

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, our estimates include the collectability of our accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

 

 
17
 
Table of Contents

 

Investments

 

Through March 31, 2018, we used either the equity method or the cost method of accounting. We use the equity method for unconsolidated equity investments in which we are considered to have significant influence over the operations of the investee. We use the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, we write down the cost basis of the investment to a new cost basis that represents realizable value.

 

On April 1, 2018 we adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, we measure our equity investments at their fair value at end of each reporting period.

 

Investments accounted for under the equity method or cost method of accounting above are included in the caption “Equity investments” in our Condensed Consolidated Balance Sheets.

 

Recent Accounting Pronouncements

 

See our discussion of recent accounting policies in Footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s principal executive officer and principal financial officer. Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of September 30, 2018, our disclosure controls and procedures were not effective.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the six months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

 
18
 
Table of Contents

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Currently we are subject to any pending litigation or legal proceeding.

 

Item 1A. Risk Factors.

 

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act we are not required to provide the information required under this item.

 

Item 2. Unregistered Sales of Securities and Use of Proceeds.

 

Not applicable

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

None.

 

Item 5. Other Information.

 

On June 6, 2018, the Company offered and sold one convertible promissory note (the “Note”) in the principal amount of $100,000. The note is due December 31, 2018, bears interest at 8% per month, and in convertible at any time, in the sole discretion of the holder of the Note, into shares of common stock of the Company at purchase price of $1.00 per share. The Company made the offering to an “accredited investor” in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506, promulgated thereunder.

 

On August 1, 2018, the Company offered and sold one convertible promissory note (the “Second Note”) in the principal amount of $100,000. The note is due December 31, 2018, bears interest at 8% per month, and in convertible at any time, in the sole discretion of the holder of the Second Note, into shares of common stock of the Company at purchase price of $1.00 per share. The Company made the offering to an “accredited investor” in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506, promulgated thereunder.

 

 
19
 
Table of Contents

 

Item 6. Exhibits.

 

(a) Exhibits required by Item 601 of Regulation SK.

 

Number

Description

 

2.1

Share Exchange Agreement, dated November 4, 2016, by and among the Applied Biosciences Corp., Stony Hill Ventures Corp., a Nevada corporation, and the holders of common stock of Stony Hill Ventures Corp. (3)

 

3.1.1

Articles of Incorporation (1)

 

3.1.2

 

Certificate of Amendment (3)

 

3.1.3

 

Certificate of Change (3)

 

 

 

3.1.4

 

Certificate of Amendment (4)

 

3.2

Bylaws (2)

 

4.1

 

Convertible Promissory Note, dated June 6, 2018

 

4.2

 

Convertible Promissory Note, dated August 1, 2018

 

31.1

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

 

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS *

 

XBRL Instance Document

 

101.SCH *

 

XBRL Taxonomy Extension Schema Document

 

101.CAL *

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

101.DEF *

 

XBRL Taxonomy Extension Definition Linkbase Document

 

101.LAB *

 

XBRL Taxonomy Extension Label Linkbase Document

 

101.PRE *

 

XBRL Taxonomy Extension Presentation Linkbase Document

_________________ 

(1)

Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-197443), filed with the Securities and Exchange Commission on July 16, 2014.

(2)

Incorporated by reference to the Registrant’s Registration Statement on Form S-1/A (File No. 333-197443), filed with the Securities and Exchange Commission on October 16, 2014.

 

(3)

Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223), filed with the Securities and Exchange Commission on November 10, 2016.

 

(4)

Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223) filed with the Securities Exchange Commission on March 5, 2018

 

*

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 
20
 
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

APPLIED BIOSCIENCES CORP.

 

(Name of Registrant)

 

Date: November 14, 2018

By:

/s/ Chris Bridges

Name:

Chris Bridges

Title:

President (principal executive officer)

 

Date: November 14, 2018

By:

/s/ John James Southard

Name:

John James Southard

Title:

Secretary and Treasurer (principal accounting officer and financial officer)

 

 

21

 

EX-4.1 2 appb_ex41.htm CONVERTIBLE PROMISSORY NOTE appb_ex41.htm

EXHIBIT 4.1

 

This Promissory Note has not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be offered or sold except pursuant to an effective registration statement under the securities act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the securities act and in accordance with applicable state securities laws.

 

CONVERTIBLE PROMISSORY NOTE

 

$100,000

 

June 6, 2018

  

APPLIED BIOSCIENCES CORP.

 

Applied Biosciences Corp., a Nevada corporation (the “Company”), for value received, promises to pay to Grays Peak LLC, or any registered assigns (“Holder”) the sum of Hundred Thousand and 00/100 Dollars ($100,000.00), together with interest thereon at the rate of eight percent (8%) per annum on the unpaid balance pursuant to this Convertible Promissory Note (“Note”). The Company shall make all payments to Holder at _______________________.

 

1. Maturity Date; Interest Payments. All outstanding principal together with interest on this Note shall be due December 31st, 2018, (“Maturity Date”).

 

2. Conversion of Principal and Interest Owed.

 

(a) Optional Conversion into Common Stock. The Holder, in its sole discretion and election, may convert any part or all of the outstanding principal and/or interest on this Note into shares of common stock of the Company obtained by dividing (i) any amount of part or all of the outstanding principal and/or interest on this Note, by (ii) $_______. If the Holder of this Note elects to make a conversion hereunder, then the Holder shall effect a conversion by delivering to the Company a completed Notice of Conversion, the form of which is attached hereto as Annex A, not later than three days after the date of conversion on such notice. Holder shall make delivery of such notice by way of e-mail attachment e-mailed to the President of the Company, provided receipt of such e-mail is confirmed by return e-mail by the President of the Company, or by delivery of the notice to: 9701 Wilshire Blvd., Suite 1000, Beverly Hills, California 90212.

 

3. Registered Owner. The Company may treat the person or persons whose name or names appear on this Note as the absolute owner or owners hereof for the purpose of receiving payment of, or on account of, the principal and interest due on this Note and for all other purposes.

 

4. Representations and Warranties of the Company.

 

(a) Due Incorporation, Qualification, etc. The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation; and (ii) has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

(b) Authority. The execution, delivery and performance by the Company of this Note and the performance of the obligations contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the Company.

 

(c) Enforceability. This Note has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

 

- 1 -

 
 

 

(d) Non-Contravention. The execution and delivery by the Company of this Note and the performance of the obligations contemplated hereby does not and will not (i) violate any law, statute, rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the giving of notice or lapse of time or both), the Certificate of Incorporation or Bylaws of the Company or any contract, agreement or instrument to which the Company is a party or by which any of its properties may be bound, or any order, decree or judgment binding upon the Company or any of its properties; or (iii) result in the creation or imposition of any lien or encumbrance upon any property or asset of the Company.

 

(e) Approvals. No consent, approval, order or authorization of, or registration, declaration, qualification or filing with, any governmental authority or other person is required in connection with the execution and delivery of the Note and the performance of the obligations contemplated hereby.

 

5. Representations and Warranties of the Holder.

 

(a) No Public Sale or Distribution. The Holder of this Note, by acceptance of this Note, agrees and acknowledges that such Holder is acquiring the Note for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under federal and state securities laws. Such Holder is acquiring the Note hereunder in the ordinary course of its business. Such Holder presently does not have any agreement or understanding, directly or indirectly, with any person to distribute the Note.

 

6. Waivers and Acceleration. The Company hereby waives diligence, presentment, protest, demand of payment, notice of protest, dishonor and nonpayment, and waives the legal effect of Holder’s failure to give all notices not expressly provided for herein. All sums due under this Note shall, at the election of Holder, be immediately due and payable upon the happening of any one or more of the following events of default: (a) the Company defaults in the performance of or compliance with any term of this Note; (b) the Company makes a general assignment for the benefit of creditors; (c) the Company applies for or consents to the appointment of a receiver of the whole or any substantial part of the Company’s assets; (d) the Company files a voluntary petition in bankruptcy or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any insolvency law or an answer admitting material allegations of a petition filed against the Company in any bankruptcy, reorganization or insolvency proceedings; or (e) an order, judgment, or decree is entered, without the application approval, or a consent of Company by any court of competent jurisdiction adjudging Company to be a bankrupt or approving a petition appointing a receiver, trustee, or liquidator of the whole or any substantial part of the assets of Company, and such order, judgment, or decree is not vacated or set aside or stayed within thirty (30) days from the date of its entry.

 

7. Usury. Notwithstanding any other provision of this Note to the contrary, all agreements between the Company and the Holder of this Note are expressly limited so that in no event or contingency shall the amount paid or agreed to be paid to the Holder of this Note for the use, forbearance or detention of the money to be advanced under this Note exceed the highest lawful rate permissible under applicable laws.

 

8. Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Note or the rights and duties of the parties in relation hereto, the prevailing party will be entitled, in addition to any other relief granted, to all costs and expenses incurred by any prevailing party, including, without limitation, all reasonable attorneys’ fees. This note shall take effect as a sealed instrument and shall be construed, governed and enforced in accordance with the laws of the State of New York.

 

9. Transfer of Note. This Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Holder shall provide the Company with prompt notice of any transfer of this Note; provided, however, that failure to provide such notice shall not void the transfer. Thereupon, a new Note for like principal amount will be issued to, and registered in the name of, the transferee.

 

THE COMPANY:

 

APPLIED BIOSCIENCES CORP.

     
By: /s/ John Brady

Name:

John Brady

 
Title:

Secretary

 

 

 

- 2 -

 
 

 

ANNEX A

 

NOTICE OF CONVERSION

 

The undersigned hereby elects to convert principal and/or interest under the Convertible Promissory Note due ________________, of Applied Biosciences Corp., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

 

The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock.

 

Conversion calculations:

Date to Effect Conversion:

 

Principal Amount of Note to be Converted:

 

Payment of Interest in Common Stock __ yes __ no

If yes, $_____ of Interest Accrued on Account of Conversion at Issue.

 

Number of shares of Common Stock to be issued:

 

Signature:

 

Name:

 

 

DWAC Instructions:

       

Broker No:

 

Account No:

 
       

 

- 3 -

 

EX-4.2 3 appb_ex42.htm CONVERTIBLE PROMISSORY NOTE appb_ex42.htm

EXHIBIT 4.2

 

 

This Promissory Note has not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be offered or sold except pursuant to an effective registration statement under the securities act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the securities act and in accordance with applicable state securities laws.

 

CONVERTIBLE PROMISSORY NOTE

 

$100,000

 August 1, 2018

  

APPLIED BIOSCIENCES CORP.

 

Applied Biosciences Corp., a Nevada corporation (the “Company”), for value received, promises to pay to Grays Peak LLC, or any registered assigns (“Holder”) the sum of Hundred Thousand and 00/100 Dollars ($100,000.00), together with interest thereon at the rate of eight percent (8%) per month on the unpaid balance pursuant to this Convertible Promissory Note (“Note”). The Company shall make all payments to Holder at _______________________.

 

1. Maturity Date; Interest Payments. All outstanding principal together with interest on this Note shall be due December 31st, 2018, (“Maturity Date”).

 

2. Conversion of Principal and Interest Owed.

 

(a) Optional Conversion into Common Stock. The Holder, in its sole discretion and election, may convert any part or all of the outstanding principal and/or interest on this Note into shares of common stock of the Company obtained by dividing (i) any amount of part or all of the outstanding principal and/or interest on this Note, by (ii) $1.00. If the Holder of this Note elects to make a conversion hereunder, then the Holder shall effect a conversion by delivering to the Company a completed Notice of Conversion, the form of which is attached hereto as Annex A, not later than three days after the date of conversion on such notice. Holder shall make delivery of such notice by way of e-mail attachment e-mailed to the President of the Company, provided receipt of such e-mail is confirmed by return e-mail by the President of the Company, or by delivery of the notice to: 9701 Wilshire Blvd., Suite 1000, Beverly Hills, California 90212.

 

3. Registered Owner. The Company may treat the person or persons whose name or names appear on this Note as the absolute owner or owners hereof for the purpose of receiving payment of, or on account of, the principal and interest due on this Note and for all other purposes.

 

4. Representations and Warranties of the Company.

 

(a) Due Incorporation, Qualification, etc. The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation; and (ii) has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

(b) Authority. The execution, delivery and performance by the Company of this Note and the performance of the obligations contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the Company.

 

(c) Enforceability. This Note has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

(d) Non-Contravention. The execution and delivery by the Company of this Note and the performance of the obligations contemplated hereby does not and will not (i) violate any law, statute, rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the giving of notice or lapse of time or both), the Certificate of Incorporation or Bylaws of the Company or any contract, agreement or instrument to which the Company is a party or by which any of its properties may be bound, or any order, decree or judgment binding upon the Company or any of its properties; or (iii) result in the creation or imposition of any lien or encumbrance upon any property or asset of the Company.

  

 
-1-
 
 

 

(e) Approvals. No consent, approval, order or authorization of, or registration, declaration, qualification or filing with, any governmental authority or other person is required in connection with the execution and delivery of the Note and the performance of the obligations contemplated hereby.

 

5. Representations and Warranties of the Holder.

 

(a) No Public Sale or Distribution. The Holder of this Note, by acceptance of this Note, agrees and acknowledges that such Holder is acquiring the Note for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under federal and state securities laws. Such Holder is acquiring the Note hereunder in the ordinary course of its business. Such Holder presently does not have any agreement or understanding, directly or indirectly, with any person to distribute the Note.

 

6. Waivers and Acceleration. The Company hereby waives diligence, presentment, protest, demand of payment, notice of protest, dishonor and nonpayment, and waives the legal effect of Holder’s failure to give all notices not expressly provided for herein. All sums due under this Note shall, at the election of Holder, be immediately due and payable upon the happening of any one or more of the following events of default: (a) the Company defaults in the performance of or compliance with any term of this Note; (b) the Company makes a general assignment for the benefit of creditors; (c) the Company applies for or consents to the appointment of a receiver of the whole or any substantial part of the Company’s assets; (d) the Company files a voluntary petition in bankruptcy or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any insolvency law or an answer admitting material allegations of a petition filed against the Company in any bankruptcy, reorganization or insolvency proceedings; or (e) an order, judgment, or decree is entered, without the application approval, or a consent of Company by any court of competent jurisdiction adjudging Company to be a bankrupt or approving a petition appointing a receiver, trustee, or liquidator of the whole or any substantial part of the assets of Company, and such order, judgment, or decree is not vacated or set aside or stayed within thirty (30) days from the date of its entry.

 

7. Usury. Notwithstanding any other provision of this Note to the contrary, all agreements between the Company and the Holder of this Note are expressly limited so that in no event or contingency shall the amount paid or agreed to be paid to the Holder of this Note for the use, forbearance or detention of the money to be advanced under this Note exceed the highest lawful rate permissible under applicable laws.

 

8. Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Note or the rights and duties of the parties in relation hereto, the prevailing party will be entitled, in addition to any other relief granted, to all costs and expenses incurred by any prevailing party, including, without limitation, all reasonable attorneys’ fees. This note shall take effect as a sealed instrument and shall be construed, governed and enforced in accordance with the laws of the State of New York.

 

9. Transfer of Note. This Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Holder shall provide the Company with prompt notice of any transfer of this Note; provided, however, that failure to provide such notice shall not void the transfer. Thereupon, a new Note for like principal amount will be issued to, and registered in the name of, the transferee.

 

THE COMPANY:

 

APPLIED BIOSCIENCES CORP.

     
By:

/s/ John Brady

Name:

John Brady  
Title: Secretary  

 

 
-2-
 
 

 

ANNEX A

 

NOTICE OF CONVERSION

 

The undersigned hereby elects to convert principal and/or interest under the Convertible Promissory Note due ________________, of Applied Biosciences Corp., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

 

The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock.

 

Conversion calculations:

Date to Effect Conversion:

 

Principal Amount of Note to be Converted:

 

Payment of Interest in Common Stock __ yes __ no

If yes, $_____ of Interest Accrued on Account of Conversion at Issue.

 

Number of shares of Common Stock to be issued:

 

Signature:

 

Name:

 

DWAC Instructions:

 

Broker No:

Account No:

 

 
-3-

 

 

EX-31.1 4 appb_ex311.htm CERTIFICATION appb_ex311.htm

EXHIBIT 31.1

 

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES CORP.

 

I, Chris Bridges, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;

 

2.

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: November 14, 2018

By:

/s/ Chris Bridges

 

Chris Bridges

 

President (principal executive officer)

 

EX-31.2 5 appb_ex312.htm CERTIFICATION appb_ex312.htm

EXHIBIT 31.2

 

SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES CORP.

 

I, John James Southard, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;

 

2.

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: November 14, 2018

By:

/s/ John James Southard

 

John James Southard

 

Secretary (principal accounting officer and principal financial officer)

 

EX-32.1 6 appb_ex321.htm CERTIFICATION appb_ex321.htm

EXHIBIT 32.1

 

SECTION 906 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES CORP.

 

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the six months ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Chris Bridges, President of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

 

 

Date: November 14, 2018

By:

/s/ Chris Bridges

 

Chris Bridges

 

 

President

 

 

(principal executive officer)

 

EX-32.2 7 appb_ex322.htm CERTIFICATION appb_ex322.htm

EXHIBIT 32.2

 

SECTION 906 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES CORP.

 

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the six months ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John James Southard, Secretary of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

 

 

Date: November 14, 2018

By:

/s/ John James Southard

 

John James Southard

 

 

Secretary and Treasurer

 

 

(principal accounting officer and principal financial officer)

 

EX-101.INS 8 appb-20180930.xml XBRL INSTANCE DOCUMENT 0001607549 2018-04-01 2018-09-30 0001607549 2018-11-09 0001607549 2018-03-31 0001607549 2018-09-30 0001607549 us-gaap:SeriesAPreferredStockMember 2016-11-30 0001607549 us-gaap:CommonClassAMember 2017-01-31 0001607549 appb:CannabTechLtdMember 2018-03-31 0001607549 appb:HightimesHoldingsCorpMember 2018-03-31 0001607549 appb:PrecisionCultivationSystemsLLCMember 2017-06-30 0001607549 appb:PrecisionCultivationSystemsLLCMember 2017-06-01 2017-06-30 0001607549 appb:MCigLLCMember 2017-02-23 0001607549 appb:PrecisionCultivationSystemsLLCMember 2018-03-31 0001607549 us-gaap:SeriesAPreferredStockMember 2016-11-01 2016-11-30 0001607549 us-gaap:SeriesAPreferredStockMember 2017-10-31 0001607549 us-gaap:SeriesAPreferredStockMember 2017-10-02 2017-10-31 0001607549 us-gaap:CommonClassAMember 2017-01-02 2017-01-31 0001607549 us-gaap:CommonStockMember 2018-03-31 0001607549 appb:CommonStockToBeIssuedMember 2018-03-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001607549 us-gaap:NoncontrollingInterestMember 2018-03-31 0001607549 us-gaap:RetainedEarningsMember 2018-03-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-03-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-01-31 0001607549 appb:CannabiTechLtdMember 2018-03-31 0001607549 2017-03-31 0001607549 appb:AppliedProductsLLCMember appb:VitaCBDLLCMember 2018-04-01 2018-09-30 0001607549 appb:CannabTechLtdMember 2018-09-30 0001607549 appb:HightimesHoldingsCorpMember 2018-09-30 0001607549 appb:PrecisionCultivationSystemsLLCMember 2018-09-30 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-09-30 0001607549 appb:ConvertiblePromissoryNotesMember 2018-09-30 0001607549 appb:ConvertiblePromissoryNotesOneMember 2018-09-30 0001607549 appb:ConvertiblePromissoryNotesTwoMember 2018-09-30 0001607549 appb:ConvertiblePromissoryNotesMember 2018-04-01 2018-09-30 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-01-01 2018-01-31 0001607549 2017-04-01 2017-09-30 0001607549 2017-07-01 2017-09-30 0001607549 2018-07-01 2018-09-30 0001607549 2017-09-30 0001607549 appb:CannabiTechLtdMember 2018-03-01 2018-03-31 0001607549 appb:ConvertiblePromissoryNotesThreeMember 2018-09-30 0001607549 us-gaap:CommonStockMember 2018-04-01 2018-09-30 0001607549 us-gaap:CommonStockMember 2018-09-30 0001607549 appb:CommonStockToBeIssuedMember 2018-04-01 2018-09-30 0001607549 appb:CommonStockToBeIssuedMember 2018-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-09-30 0001607549 us-gaap:RetainedEarningsMember 2018-04-01 2018-09-30 0001607549 us-gaap:RetainedEarningsMember 2018-09-30 0001607549 us-gaap:InvestorMember 2018-04-01 2018-09-30 0001607549 us-gaap:InvestorMember 2018-09-30 0001607549 appb:ConsultingAgreementMember appb:ThreeConsultantsMember 2018-09-30 0001607549 us-gaap:SubsequentEventMember appb:NonBindingLetterAgreementMember 2018-10-15 0001607549 us-gaap:SubsequentEventMember 2018-10-01 2018-10-15 0001607549 appb:AssetPurchaseAgreementMember 2018-04-01 2018-09-30 0001607549 appb:AdvisoryBoardMember 2018-04-01 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure appb:Number APPLIED BIOSCIENCES CORP. 0001607549 10-Q 2018-09-30 false --03-31 Yes Non-accelerated Filer Q2 2019 11772113 0.00001 0.00001 2.00 -515516 -374611 -177407 -113759 -9592 -505924 10499610 10677110 75000 195055 75000 100000 468537 873300 68237 250000 50000 100000 68537 68537 654763 50000 100000 0.00001 0.00001 5000000 5000000 0 0 0 0 200000000 200000000 263000 212000 10499610 10677110 10499610 10677110 2227 50000 1 -100000 99999 51000 51000 51000 128605 128605 164500 164500 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Description of the Company</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Applied BioSciences Corp. (formerly First Fixtures, Inc. and Stony Hill Corp. or the &#8220;Company&#8221;) was incorporated in the State of Nevada on February 21, 2014 and established a fiscal year end of March 31. Effective October 24, 2016 the Company changed its name from First Fixtures Inc. to Stony Hill Corp and on March 6, 2018, the Company changed its name from Stony Hill Corp. to Applied BioSciences Corp. The Company is focused on multiple areas of the hemp and CBD industry. Specifically, the Company is focused on select investments, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Basis of presentation &#8211; Unaudited Financial Statements</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019, or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended March 31, 2018, which are included in the Company&#8217;s Report on Form 10-K for such year filed on June 28, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Going concern</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">These condensed statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As reflected in the condensed consolidated financial statements, the Company incurred a net loss of $515,516 and used $293,510 of cash in operating activities during the six months ended September 30, 2018. Further, the Company&#8217;s independent auditor in their audit report for fiscal year ended March 31, 2018 expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. These and other factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and income from operations. During the six months ended September 30, 2018, the Company sold 37,500 shares of its common stock to accredited investors at a price of $2.00 per share for total proceeds of $75,000 and issued three separate convertible notes for a total amount of $164,500 both in private placements to accredited investors. However, the Company will need and is currently working on obtaining additional funds to operate its business through and beyond the date of this Form 10-Q filing. There is no assurance that such funds will be available or at terms acceptable to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions and covenants on its operations, in the case of debt financing or cause substantial dilution for its stockholders in the case of convertible debt and equity financing.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Equity investments relate to purchases of stock in certain entities with ownership percentages of less than 5%. As of March 31, 2018, these investments were recorded at their cost basis. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, and as such, these investments were recorded at their market value as of September 30, 2018. The investments consist of the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2018</b></font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font: 10pt Times New Roman, Times, Serif">(A)&#160;&#160;&#160; Cannabi-Tech Ltd.</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,537</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,237</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font: 10pt Times New Roman, Times, Serif">(B)&#160;&#160;&#160; Hightimes Holdings Corp.</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">654,763</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font: 10pt Times New Roman, Times, Serif">(C)&#160;&#160;&#160; Precision Cultivation Systems, LLC</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font: 10pt Times New Roman, Times, Serif">(D)&#160;&#160;&#160; Bailey Venture Partners XII LLC (JUUL)</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">873,300</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">468,537</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">(A) In November 2016, the Company purchased 29,571 shares of Preferred A stock of Cannabi-Tech Ltd. (&#8220;Cannabi&#8221;), at a price of $1.69086 per share for total investment of $50,000. In October 2017, the Company purchased 7,309 shares of Preferred A-1 stock of Cannabi at a price of $2.536 per share for total investment of $18,537. As of March 31, 2018, total investment amounted to $68,537, which accounts for less than 5% in Cannabi. Cannabi is a private company incorporated in the State of Israel that provides lab-grade medical cannabis quality control testing systems used to test the quality of medical marijuana flowers. The fair value of the investment at September 30, 2018 approximated its cost basis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">(B) In January 2017, the Company entered in to an agreement to purchase 59,524 shares of Class A common stock at a price of $4.20 per share for total investment of $250,000, which accounts for less than 5% investment in Hightimes Holdings Corp. (&#8220;Hightimes&#8221;). Hightimes owns Hight Times Magazine and hosts festivals, events and competitions including the High Times Cannabis Cup and multiple e-commerce properties, including HighTimes.com, CannabisCup.com and 420.com. As of September 30, 2018, the Company was able to obtain observable evidence that the investment had a market value of $11.00 per share, or an aggregate value of $654,763. As such, the Company recorded an unrealized gain from the change in market value of $404,763 during the six months ended September 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">(C) In June 2017, the Company entered in a Subscription Agreement to purchase 0.5% interest in Precision Cultivation Systems, LLC (&#8220;Precision&#8221;), a Delaware limited liability company, for a purchase price of $50,000. Precision is developing a growth system that capitalizes on a patent-pending cultivation method that utilizes proprietary irrigation and root zone conditioning. As part of the Subscription Agreement, $42,500 of the investment is subject to repayment on a pro-rata basis with other investors who have entered into similar Subscription Agreements. Amounts subject to repayment are solely at the discretion of Precision. The fair value of the investment at September 30, 2018 approximated its cost basis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">(D) In January 2018, the Company paid $100,000 for the purchase of a Membership Interest in Bailey Venture Partners XII LLC (&#8220;Bailey&#8221;) representing less than 5% interest in Bailey. Along with other funds received from third-party investors, Bailey plans to invest funds received in various strategic investments. The Company recorded this investment at cost and will recognize dividends, if any, when received, and will recognize gains or loss upon either selling the securities or recognize a loss prior to selling the securities if there is evidence that the fair market value of the investment has declined to below the recorded historical cost. The fair value of the investment at September 30, 2018 approximated its cost basis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">As the Company does not participate in the management of these companies nor has the ability to exercise significant influence over these companies, the Company recorded these investments at cost, and as of April 1, 2018, will adjust the cost basis to market at the end of each reporting period. Dividends, if any, will be recognized when received.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During the six months ended September 30, 2018, the Company issued three separate Convertible Promissory Notes (&#8220;Notes&#8221;) having a total available principal amount of $250,000 to the same holder of which the Company borrowed $164,500 as of September 30, 2018. All outstanding principal together with interest on this Note is due and payable on December 31, 2018 and accrue interest at 8% per month. The note holder, at its sole discretion and election, may convert any part or all of the then outstanding principal and/or interest on these Notes into shares of common stock of the Company at a fixed price per share of $1.00. As the conversion price of $1.00 reflected a price discount below the fair market value of the Company&#8217;s common stock as of the date of the receipt of proceeds, there was deemed a beneficial conversion feature associated with these Notes. As such, the Company recorded $128,605 in additional paid-in capital and debt discount representing the intrinsic value of the beneficial conversion feature at the date of the borrowing against the Notes. The value of the beneficial conversion feature is being amortized over the term of the Notes of which $42,715 was amortized and reflected as interest expense for the six months ended September 30, 2018. As of September 30, 2018, the unamortized debt discount was $85,890. As of September 30, 2018, the balance of the $164,500 note, net of the unamortized discount of $85,890 was $78,610.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In view of the Company&#8217;s limited operations and resources, none of the Company&#8217;s directors and/or officers received any compensation from the Company during the six months ended September 30, 2018.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Common Stock to be Issued</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On February 23, 2017, the Company entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with mCig, Inc., a Nevada corporation (&#8220;mCig&#8221;) consisting of the issuance of an aggregate of 350,000 shares of common stock. Of the 350,000 shares of common stock consideration, 150,000 shares or $426,000 have not been issued as of March 31, 2018 and have been included in &#8220;Common stock to be issued&#8221; in the accompanying condensed consolidated statement of stockholders&#8217; equity. During the six months ended September 30, 2018, the Company issued 50,000 shares of common stock valued at $100,000 which was previously reflected as &#8220;Common stock to be issued&#8221; in the condensed consolidated statement of stockholders&#8217; equity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During the six months ended September 30, 2018, the Company sold 37,500 shares of common stock, of which 25,000 shares had not been issued as of September 30, 2018 and is reflected in &#8220;Common stock to be issued&#8221; in the condensed consolidated statement of stockholders&#8217; equity. The shares were sold at a price of $2.00 per share for total proceeds of $75,000 pursuant to a private placement Subscription Agreement with accredited investors. The Subscription Agreement offered up to one million shares of the Company&#8217;s common stock at a price per share of $2.00 per share. The Company made this offering solely to accredited investors, as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Establishment of Advisory Board and Adoption of Charter</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On April 28, 2017, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the &#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. The Advisory Board shall be comprised of one or more directors (&#8220;Advisors&#8221;), and up to nine independent, non-Board, non-employee members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During the six months ended September 30, 2018, the Company appointed another Advisor to the Advisory Board, which entitled him to an annual consulting fee 25,000 shares of the Company&#8217;s stock for a term of 6 months, with total fair value of $51,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Shares Issued for Services</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During the six months ended September 30, 2018, the Company granted an aggregate of 99,500 shares of its common stock to three (3) consultants as payment for services rendered to the Company and recorded expense of $241,852 based on the fair value of the Company&#8217;s common stock at grant dates. Of the 99,500 shares granted, 62,000 shares valued at $61,852 had not been issued as of September 30, 2018, and were reflected in &#8220;Common stock to be issued&#8221; in the condensed consolidated statement of stockholders&#8217; equity during the period then ended.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Common Stock Purchase Agreement</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On October 15, 2018, the Company entered into a Common Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Triton Funds, LP, a Delaware limited partnership (the &#8220;Purchaser&#8221;), pursuant to which the Purchaser has the right to right to purchase up to $1,000,000 of shares of common stock (the &#8220;Shares&#8221;) of the Company at a purchase price equal to 75% of the lowest closing price of the common stock of the Company on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than $300,000 of common stock of the Company within a period of every 30 business days. The Company has the right to terminate the Purchase Agreement at any time, and the Purchase Agreement shall terminate automatically on June 30, 2019, unless earlier terminated. The Purchase Agreement also contains customary representations, warranties, and covenants by, among, and for the benefit of the parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On October 15, 2018, the Company entered into a non-binding letter agreement, pursuant to which the Company intends to issue 25,000 shares of common stock to the Purchaser, pursuant to a Share Donation Agreement to be entered into by and between the Company and the Purchaser at a future, unspecified date. The Company anticipates making the issuance of 25,000 shares on a date before December 31, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s offering of the Shares to the Purchaser is exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2) of the Act (in that the Shares were offered by us in a transaction not involving any public offering) and pursuant to Rule 506 of Regulation D, promulgated thereunder.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company has reclassified prior year sales and marketing expenses of $45,496 and $65,061 for the three and six months ended September 30, 2017, respectively, that were previously included in general and administrative expenses in the condensed consolidated statements of operations to conform to the current year presentation. The reclassification of sales and marketing expenses had no impact on net loss or cash flows.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses advertising costs as incurred. Advertising expense for the three and six months ended September 30, 2018 amounted to $111,392 and $455,437, respectively, and $45,496 and $65,061 for the three and six months ended September 30, 2017 and are included in &#8220;Sales and Marketing expenses&#8221; in the Condensed Consolidated Statements of Operations.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The basic earnings (loss) per share is calculated by dividing the Company&#8217;s net income (loss) available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company&#8217;s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statements.</font></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font-size: 10pt">(A)&#160;&#160;&#160; Cannabi-Tech Ltd.</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">68,537</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">68,237</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font-size: 10pt">(B)&#160;&#160;&#160; Hightimes Holdings Corp.</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">654,763</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">250,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font-size: 10pt">(C)&#160;&#160;&#160; Precision Cultivation Systems, LLC</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">50,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">50,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify; text-indent: 11.25pt"><font style="font-size: 10pt">(D)&#160;&#160;&#160; Bailey Venture Partners XII LLC (JUUL)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">100,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">100,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">873,300</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">468,537</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <p style="margin: 0pt"></p> Nevada 2014-02-21 12500 37500 50000 2.00 0.80 29571 59524 50000 7309 100000 1.69086 4.20 2.536 50000 18537 250000 ownership percentages of less than 5% <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">accounts for less than 5% investment in Hightimes Holdings Corp.</font></p> <p style="margin: 0">representing less than 5% interest in Bailey.</p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">accounts for less than 5% in Cannabi.</font></p> 0.005 42500 11.00 250000 250000 250000 1.00 1.00 85890 350000 705327 1006771 -9027 -18619 -2901933 -3407857 526000 537852 3054297 3538900 105 107 35885 356388 14039 238029 78610 21846 39749 705327 1006771 5500 5500 4441 3855 226849 124116 124455 54455 29074 51672 12386 11065 10617332 15268914 15320154 10677110 -0.05 -0.02 -0.01 -0.01 -505924 -375750 -177350 -110423 -9592 1139 -57 -3336 68301 66422 404763 245834 -851978 -374611 -177407 -293171 851220 400833 186243 299737 585 112256 56128 292 395198 223516 84619 188052 455437 65061 45496 111393 -758 26222 8836 6566 60158 90389 52443 42400 336462 179412 128605 37500 60934 6924 212637 147484 -54010 -65153 239500 195055 -50000 50000 -293510 -210208 241893 11805 107500 1382 -22598 -7648 1321 -3392 112256 586 255352 50000 42715 0.08 75000 50000 25000 90000 241852 1 61852 179999 25000 25000 150000 25000 62000 499945 25000 <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company entered into a Common Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Triton Funds, LP, a Delaware limited partnership (the &#8220;Purchaser&#8221;), pursuant to which the Purchaser has the right to right to purchase up to $1,000,000 of shares of common stock (the &#8220;Shares&#8221;) of the Company at a purchase price equal to 75% of the lowest closing price of the common stock of the Company on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than $300,000 of common stock of the Company within a period of every 30 business days. The Company has the right to terminate the Purchase Agreement at any time, and the Purchase Agreement shall terminate automatically on June 30, 2019, unless earlier terminated.</font></p> 669442 650383 105 526000 3054297 -9027 -2901933 107 537852 3538900 -18619 -3407857 678469 669002 59400 116611 61279 48966 false true 426000 61852 99500 241852 P6M 3 2018-12-31 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Principles of Consolidation</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Reclassification of Certain Prior Year Information&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company has reclassified prior year sales and marketing expenses of $45,496 and $65,061 for the three and six months ended September 30, 2017, respectively, that were previously included in general and administrative expenses in the condensed consolidated statements of operations to conform to the current year presentation. The reclassification of sales and marketing expenses had no impact on net loss or cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Use of Estimates and Assumptions</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Revenue Recognition</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Advertising</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses advertising costs as incurred. Advertising expense for the three and six months ended September 30, 2018 amounted to $111,392 and $455,437, respectively, and $45,496 and $65,061 for the three and six months ended September 30, 2017 and are included in &#8220;Sales and Marketing expenses&#8221; in the Condensed Consolidated Statements of Operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Earnings (Loss) per Share </b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The basic earnings (loss) per share is calculated by dividing the Company&#8217;s net income (loss) available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company&#8217;s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Investments</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Investments&#160;accounted for&#160;as above&#160;are included in the caption &#8220;Equity investments&#8221; on the Condensed Consolidated Balance Sheets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Recent Accounting Pronouncements</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Investments&#160;accounted for&#160;as above&#160;are included in the caption &#8220;Equity investments&#8221; on the Condensed Consolidated Balance Sheets.</font></p> EX-101.SCH 9 appb-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CONVERTIBLE NOTE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - CONVERTIBLE NOTE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 appb-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 appb-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 appb-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Series A preferred stock [Member] Common stock A [Member] Equity Components [Axis] Cannabi-Tech Ltd [Member] Hightimes Holdings Corp [Member] Precision Cultivation Systems, LLC [Member] Title of Individual [Axis] mCig LLC [Member] Common Stock $0.00001 Par Common Stock to be Issued Additional Paid-In Capital Non-Controlling Interest Accumulated Deficit Bailey Venture Partners XII LLC [Member] Cannabi-Tech Ltd. [Member] Plan Name [Axis] Applied Products LLC [Member] VitaCBD LLC [Member] Debt Instrument [Axis] Convertible Promissory Notes [Member] Convertible Promissory Notes One [Member] Convertible Promissory Notes Two [Member] Convertible Promissory Notes Three [Member] Related Party [Axis] Investor [Member] Consulting Agreement [Member] Three Consultants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Non-binding letter Agreement [Member] Asset Purchase Agreement [Member] Advisory Board [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Emerging Growth Company Entity Small Business Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable, net of allowance of nil and $2,227 at September 30, 2018 (unaudited) and March 31, 2018, respectively Inventory Prepaids and other current assets Total Current Assets Property and equipment, net Equity investments Other asset TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable Convertible note payable, net of debt discount of $85,890 at September 30, 2018 Accrued expenses Total Current Liabilities Stockholders' Equity Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018 Common stock; $0.00001 par value; 200,000,000 shares authorized; 10,677,110 and 10,499,610 issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018, respectively Additional paid in capital Common stock to be issued, 212,000 and 263,000 shares at September 30, 2018 (unaudited) and March 31, 2018, respectively Accumulated deficit Total Applied BioSciences Corp. Stockholders' Equity Non-controlling interest Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Accounts receivable, net of allowance Convertible note payable net of debt discount Preferred stock, par value Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Common stock shares to be issued Condensed Consolidated Statements Of Operations PRODUCT REVENUE, NET COST OF REVENUE, PRODUCT GROSS (LOSS) MARGIN EXPENSES Sales and marketing General and administrative Depreciation and Amortization TOTAL OPERATING EXPENSES OPERATING LOSS Other Income (Expense) Unrealized gain on equity investments Interest Expense Total other income, net NET LOSS Less: Net loss (income) attributable to non controlling interest NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. LOSS PER COMMON SHARE WEIGHTED AVERAGE SHARES OUTSTANDING Basic and diluted Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Issuance of common stock previously committed but not issued, Share Issuance of common stock previously committed but not issued, Amount Issuance of common stock for cash, Share Issuance of common stock for cash, Amount Fair value of shares issued to consultants for services, Share Fair value of shares issued to consultants for services, Amount Fair value of shares issued to advisory board member, Share Fair value of shares issued to advisory board member, Amount Beneficial conversion feature associated with a convertible note Net loss Ending Balance, Shares Ending Balance, Amount Condensed Consolidated Statements Of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES Adjustment to reconcile net loss to net cash used in operating activities: Unrealized gain on equity investments Non-cash interest expense Fair value of shares issued to consultants Depreciation Amortization of intangible Changes in operating assets and liabilities Accounts receivable Inventory Prepaid and other current assets Accounts payable and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Acquisition of equity investment Net cash used in investing activities CASH FLOW FROM FINANCING ACTIVITIES Issuance of convertible note Issuance of common stock for cash Net cash provided by financing activities NET CHANGE IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD NON-CASH INVESTING AND FINANCING ACTIVITIES Fair value of shares issued to consultants recorded as prepaid Fair value of beneficial conversion feature related to issuance of convertible notes Increase in cash held in trust account from sale of common stock Notes to Financial Statements NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 3 - INVESTMENTS NOTE 4 - CONVERTIBLE NOTE NOTE 5 - RELATED PARTY TRANSACTIONS NOTE 6 - EQUITY NOTE 7 - SUBSEQUENT EVENTS Summary Of Significant Accounting Policies Principles of Consolidation Reclassification of Certain Prior Year Information Use of Estimates and Assumptions Revenue Recognition Advertising Earnings (Loss) per Share Investments Recent Accounting Pronouncements Investments Stock equity investments State of incorporation Date of incorporation Net cash used in operating activities Common stock, price per share Number of convertible notes Owned Interest entity Sales and marketing expenses Purchase of stock Stock price per share Total investment Ownership percentages description Interest rate Repayment of investment, pro-rata basis Market value per share Principal amount Fixed price per share Conversion price Interest rate Convertible debt maturity date Fair value of shares issued to advisory board member, Shares Issuance of common stock for cash, shares Sale of common stock, price per share Consulting agreement term Aggregate common stock shares issued Common stock, per share Common stock, shares unissued, shares Common stock, shares unissued, value Common stock shares granted Expense related to shares granted Common stock shares reserved for future issuance Common stock purchase agreement, description Assets, Current Assets Liabilities, Current Liabilities and Equity Gross Profit Operating Expenses Interest Expense Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Shares, Issued Increase (Decrease) in Inventories Payments to Acquire Investments Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Debt Instrument, Interest Rate During Period EX-101.PRE 13 appb-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Sep. 30, 2018
Nov. 09, 2018
Document And Entity Information    
Entity Registrant Name APPLIED BIOSCIENCES CORP.  
Entity Central Index Key 0001607549  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   11,772,113
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2019  
Entity Emerging Growth Company false  
Entity Small Business true  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Current Assets    
Cash $ 6,924 $ 60,934
Accounts receivable, net of allowance of nil and $2,227 at September 30, 2018 (unaudited) and March 31, 2018, respectively 11,065 12,386
Inventory 51,672 29,074
Prepaids and other current assets 54,455 124,455
Total Current Assets 124,116 226,849
Property and equipment, net 3,855 4,441
Equity investments 873,300 468,537
Other asset 5,500 5,500
TOTAL ASSETS 1,006,771 705,327
Current Liabilities    
Accounts payable 39,749 21,846
Convertible note payable, net of debt discount of $85,890 at September 30, 2018 78,610
Accrued expenses 238,029 14,039
Total Current Liabilities 356,388 35,885
Stockholders' Equity    
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018
Common stock; $0.00001 par value; 200,000,000 shares authorized; 10,677,110 and 10,499,610 issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018, respectively 107 105
Additional paid in capital 3,538,900 3,054,297
Common stock to be issued, 212,000 and 263,000 shares at September 30, 2018 (unaudited) and March 31, 2018, respectively 537,852 526,000
Accumulated deficit (3,407,857) (2,901,933)
Total Applied BioSciences Corp. Stockholders' Equity 669,002 678,469
Non-controlling interest (18,619) (9,027)
Total Stockholders' Equity 650,383 669,442
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,006,771 $ 705,327
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Current Assets    
Accounts receivable, net of allowance $ 2,227
Current Liabilities    
Convertible note payable net of debt discount $ 85,890
Stockholders' Equity    
Preferred stock, par value $ 0.00001 $ 0.00001
Preferred stock, authorized 5,000,000 5,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, authorized 200,000,000 200,000,000
Common stock, issued 10,677,110 10,499,610
Common stock, outstanding 10,677,110 10,499,610
Common stock shares to be issued 212,000 263,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Condensed Consolidated Statements Of Operations        
PRODUCT REVENUE, NET $ 48,966 $ 61,279 $ 59,400 $ 116,611
COST OF REVENUE, PRODUCT 42,400 52,443 60,158 90,389
GROSS (LOSS) MARGIN 6,566 8,836 (758) 26,222
EXPENSES        
Sales and marketing 111,393 45,496 455,437 65,061
General and administrative 188,052 84,619 395,198 223,516
Depreciation and Amortization 292 56,128 585 112,256
TOTAL OPERATING EXPENSES 299,737 186,243 851,220 400,833
OPERATING LOSS (293,171) (177,407) (851,978) (374,611)
Other Income (Expense)        
Unrealized gain on equity investments 245,834 404,763
Interest Expense (66,422) (68,301)
Total other income, net 179,412 336,462
NET LOSS (113,759) (177,407) (515,516) (374,611)
Less: Net loss (income) attributable to non controlling interest 3,336 57 9,592 (1,139)
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (110,423) $ (177,350) $ (505,924) $ (375,750)
LOSS PER COMMON SHARE $ (0.01) $ (0.01) $ (0.05) $ (0.02)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and diluted 10,677,110 15,320,154 10,617,332 15,268,914